Neochem͏ Bio͏ Solutions IPO ͏Opens Today With ₹93-₹98 Price Band

Mumbai, 02 December 2025: Neochem Bio Solutions Ltd. IPO opened for subscription today, a ₹44.97 crore book-building issue consisting of a fresh issue of 46,88,800 shares. The offer shall remain open for subscription until 4 December 2025, and the company will list its shares on the NSE SME platform on 9 December 2,025, subject to the final confirmations.

Incorporated in 2006, Neochem Bio Solutions Ltd. is engaged in the business of manufacturing of specialty performance chemicals. The company products are essential and used in industries such as textile & garment washing, home & personal care (HPC), institutional and industrial cleaners, water treatment, paints and coatings, paper and pulp, construction, rubber and dyes and pigments. The company has its manufacturing facility located at Saket Industrial Estate, Ahmedabad, which has an installed capacity of 22,000 metric ton per annum (“MTPA”) with a total area of 6,763 square meters.

Public Issue Structure and Key Dates Outline a Tight Subscription Window

Neochem Bio IPO is a book build issue of ₹44.97 crores. The issue is entirely a fresh issue of 0.46 crore shares of ₹44.97 crore. Neochem Bio IPO bidding opened for subscription on December 2, 2025, and will close on December 4, 2025. The allotment for the Neochem Bio IPO is expected to be finalized on December 5, 2025. Neochem Bio IPO will list on NSE SME with a tentative listing date fixed as December 9, 2025.

Neochem Bio IPO price band is set at ₹93.00 to ₹98.00 per share. The lot size for an application is 1,200. The minimum amount of investment required by an individual investor (retail) is ₹2,35,200.00 (2,400 shares) (based on upper price). The minimum lot size investment for HNI is 3 lots (3,600 shares), amounting to ₹3,52,800. Vivro Financial Services Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Rikhav Securities Ltd.

S͏trong͏ ₹12.77 Cror͏e AnchorParticipation Boosts Market Attention

Neochem Bio Solutions Ltd raised ₹ 12.77 crore by allocating 13,03,200 shares to anchor investors. The anchor lock-in period for 50% of these shares will expire on 4 January 2026, whereas the remaining portion will expire on 5 March 2026.This early anchor allocation has drawn attention to the IPO’s progress, partly because it reflects the company’s prelisting engagement with institutional participants.

Neochem Bio’s Revenue Jump of ͏39% and PAT Surge of 330% Shape Pre-Listing Focus

Neochem Bio Solutions Ltd reported significant financial upswing. Revenue increased from ₹62.01 crore in FY24 to ₹86.15 crore in FY25, registering growth of 39%, largely led by scale up across textile auxiliaries and home & personal care chemicals. Profit After Tax rose from ₹1.80 cr in FY24 to ₹7.75 crore in FY25, an exceptional increase of 330 %, supported by better operating margins and improved utilization of its 22,000 MTPA installed capacity in Ahmedabad.

It further reported revenue of ₹47.18 crore and PAT of ₹5.48 crore for the half year ending 30 September 2025, marking continued momentum in FY26. Total assets increased from ₹64.06 crore in FY24 to ₹78.89 crore in FY25 and further to ₹96.49 crore by September 2025, indicating sustained capacity and operational scaling.

Operational Indicators Reflect Improved Profitability; EBITDA Margin At 15.58%.

Key performance metrics highlight significant efficiency improvements. As at FY25, the com͏pa͏ny had R̲O̲E of 48.82%, RoCE of 41.67%, debt-to-equity of 1.80, and a PAT margin of 9%. The EBITDA margin was 15.58%, indicating better cost control ͏and product mix optimisati͏on. The Pre-Issue EPS w͏as ₹6.18, while t͏he Post-Issue EPS is estimated ₹6.41, and the estimated market capi͏tali͏sati͏on at the upper price band stands at ₹167.78 crore.

Utilisation Of IPO Proceeds Aims at Working Capital Support and Debt Reduction

The company plans to use the proceeds towards Funding the long-term working capital requirements of the company, repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by the Company, and general corporate purposes

The Neochem Bio Solutions Ltd. IPO presents key developments including anchor participation, financial performance trends and the proposed use of funds. Individuals reviewing this information may consider assessing the timeline, structure and disclosures of the offer document for a clearer understanding of the company’s operations and its planned utilisation of capital raised through the issue.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations